Oak Ridge Lab Ramps Up Production of Key Radioisotope for Cancer-Fighting Drug.
The Department of Energy's Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
Xofigo (radium Ra-223 dichloride) is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. Xofigo is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body.
Ra-223, the active ingredient in Xofigo, is currently derived from global supplies of existing Ac-227. After the U.S. Food and Drug Administration approved Xofigo in 2013, it was clear an alternative source of Ac-227 was needed. The drug is now approved in 52 countries worldwide.
With decades of experience in medical isotope research and production, ORNL was one of the few locations worldwide with the personnel and facilities necessary to develop and execute a new Ac-227 production method.
"We are excited to enter this partnership with Bayer to ensure prostate cancer patients have a reliable supply of this drug," said Jehanne Gillo, Director of the Facilities and Project Management Division for the DOE Office of Science for Nuclear Physics.
Gillo also manages the DOE Isotope Program, which produces high priority isotopes in short supply for the nation. The program sponsored the Ac-227 production development effort and spearheaded negotiations with Bayer for sustained production.
The new production process for Ac-227 begins with recovering radium-226 (Ra-226) from legacy medical devices secured by the DOE Isotope Program and diverted from a radioactive waste landfill. After recovery and extensive purification, the Ra-226 feedstock--which is fabricated into small targets--is then irradiated in the High Flux Isotope Reactor (HFIR), a DOE Office of Science User Facility at ORNL.
Once irradiation is complete, technologists use specialized nuclear facilities to dissolve the highly radioactive targets and chemically separate and purify the Ac-227 created during irradiation. The Ac-227 is then packaged in a cask and shipped to Bayer in Norway. Bayer's team periodically extracts the Ra-223 that grows into the ORNL-supplied Ac-227, via radioactive decay process, and ships it around the world for immediate use as a cancer therapy.
ORNL's team had two years to prepare facilities; undergo an extensive readiness review process; design, fabricate and install remotely operated equipment for the chemical separation and purification process; design targets for use in HFIR; develop the necessary processing chemistry; and demonstrate that the final product would meet Bayer's specifications and regulatory standards.
Source: Jason Ellis, Oak Ridge National Laboratory
Please Note: Illustration(s) are not available due to copyright restrictions.
|Printer friendly Cite/link Email Feedback|
|Publication:||Nuclear Waste News|
|Date:||May 31, 2018|
|Previous Article:||Container Problem Spurs Evacuation at Nuclear Waste Site.|
|Next Article:||Two Gallons of Radioactive Nuclear Waste is Turned to Glass.|